Sesen Bio sesenbio.com


Public list: Pharma Startups (4732) Eye Health (686)

Sesen Bio, formerly Eleven Biotherapeutics, is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer.

Sesen Bio, formerly Eleven Biotherapeutics, is a late-stage company developing next-generation antibody-drug conjugate (ADC) therapies for patients with cancer.

Company (IPO / Went public)

Phone: 617-444-8550

Fax:

245 First Street
Suite 1800
Cambridge, 02142
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Sesen Bio $114M Feb 6, 2014
Axela Biosensors $5.8M Jan 7, 2011
Helicos BioSciences $85.6M Dec 19, 2008
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Sesen Bio Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 3 investors

Competitors

Company Status Description Investors
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Il-6 antagonists and uses thereof Oct 07, 2014 Apr 24, 2018 Patent
Nucleic acid encoding chimeric il-1 receptor type i antagonists Aug 15, 2014 Oct 04, 2016 Patent
Chimeric il-1 receptor type i antagonists Jul 29, 2011 Oct 07, 2014 Patent
Albumin variants binding to fcrn May 02, 2014 Application
Chimeric cytokine formulations for ocular delivery Mar 13, 2014 Application
See all 6 patents